瑞达布韦

**瑞达布韦**
臨床資料
其他名稱	GS-9669
法律規範狀態
法律規範	美：Investigational New Drug;
识别信息
	IUPAC命名法 5-(3,3-Dimethylbut-1-yn-1-yl)-3-{(1R)-N-[(1s,4s)-4-hydroxy-4-({[(3S)-oxolan-3-yl]oxy}methyl)cyclohexyl]-4-methylcyclohex-3-ene-1-carboxamido}thiophene-2-carboxylic acid; ;
CAS号	1314795-11-3
PubChem CID	53259022;
ChemSpider	31140180;
UNII	273K4V0SPC;
化学信息
化学式	C30H41NO6S
摩尔质量	543.72 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES CC1=CC[C@@H](CC1)C(=O)N([C@H]2CC[C@](CC2)(O)CO[C@@H]3COCC3)c4c(sc(c4)C#CC(C)(C)C)C(=O)O;
	InChI InChI=1S/C30H41NO6S/c1-20-5-7-21(8-6-20)27(32)31(25-17-24(11-13-29(2,3)4)38-26(25)28(33)34)22-9-14-30(35,15-10-22)19-37-23-12-16-36-18-23/h5,17,21-23,35H,6-10,12,14-16,18-19H2,1-4H3,(H,33,34)/t21-,22-,23-,30+/m0/s1; Key:MUICUPWICXUNRS-GDCCIXDYSA-N;

瑞达布韦（INN：Radalbuvir，开发代号：GS-9669）是吉利德科学公司开发的一种用于治疗丙型肝炎病毒（HCV）感染的实验性抗病毒药物。瑞达布韦可充当NS5B抑制剂。该药物目前正处于临床试验阶段。^[1]它针对NS5B聚合酶。^[2]

参考资料

^ Search of: GS-9669 — List Results. ClinicalTrials.gov.
^ Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR. NS5B polymerase inhibitors in phase II clinical trials for HCV infection. Expert Opinion on Investigational Drugs. March 2018, 27 (3): 243–250. PMID 29271672. S2CID 3672885. doi:10.1080/13543784.2018.1420780.